Engineered immune cells take on tough childhood leukemia in new trial
NCT ID NCT03573700
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab to better recognize and kill cancer cells, and then given back to the patient. The study aims to find the safest dose, check for side effects, and see how well the therapy works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we make CAR-T cells last longer in leukemia?
- Engineered T-Cells take on childhood leukemia in early trial
- Leukemia drug shows promise in french compassionate use study
- Donor immune cells take on tough leukemia in early trial
- Can immune booster cells revive failing CAR-T therapy in leukemia?
- Hospital-Made cancer fighters: new CAR-T trial for leukemia